Literature DB >> 23104572

[Treatment resistant hypertension. Value of a new treatment concept].

M Siekierka-Harreis1, L C Rump, O Vonend.   

Abstract

Sympathetic overexpression can be found in a majority of hypertensive patients. Resistant arterial hypertension requires a targeted diagnostic procedure in order to exclude secondary causes of hypertension which can be treated specifically with established therapies. If secondary reasons are not identified, the antihypertensive medication is already optimal and lifestyle changes have been realized, but still the goal of antihypertensive therapy cannot be achieved, alternative invasive therapy strategies such as renal sympathetic denervation and baroreflex activation have been developed to achieve blood pressure control. These therapies are restricted to specialized centers which treat well-defined patients with therapy-resistant hypertension. Little long-term data concerning safety and efficacy are available for the two strategies. However, they should preferably be used as an ultima-ratio and add-on pathway to conservative procedures when established medication fails to achieve blood pressure control. To date, the effectiveness of the interventional antihypertensive therapies has only been shown on patients with systolic blood pressure over 160 mmHg and a mean oral medication of five drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23104572     DOI: 10.1007/s00108-012-3134-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  38 in total

1.  Primary aldosteronism.

Authors:  J W CONN
Journal:  J Lab Clin Med       Date:  1955-04

2.  Renal denervation in moderate to severe CKD.

Authors:  Dagmara Hering; Felix Mahfoud; Antony S Walton; Henry Krum; Gavin W Lambert; Elisabeth A Lambert; Paul A Sobotka; Michael Böhm; Bodo Cremers; Murray D Esler; Markus P Schlaich
Journal:  J Am Soc Nephrol       Date:  2012-05-17       Impact factor: 10.121

3.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

4.  Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study.

Authors:  Benjamin Kaltenbach; Jennifer Franke; Stefan C Bertog; Daniel H Steinberg; Ilona Hofmann; Horst Sievert
Journal:  Catheter Cardiovasc Interv       Date:  2012-08-13       Impact factor: 2.692

5.  Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.

Authors:  Rodrigo P Pedrosa; Luciano F Drager; Carolina C Gonzaga; Marcio G Sousa; Lílian K G de Paula; Aline C S Amaro; Celso Amodeo; Luiz A Bortolotto; Eduardo M Krieger; T Douglas Bradley; Geraldo Lorenzi-Filho
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

6.  Microvascular endothelial dysfunction in obstructive sleep apnea is caused by oxidative stress and improved by continuous positive airway pressure therapy.

Authors:  Nikolaus J Büchner; Ivo Quack; Magdalena Woznowski; Constanze Stähle; Ulrich Wenzel; Lars C Rump
Journal:  Respiration       Date:  2011-02-09       Impact factor: 3.580

7.  Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study.

Authors:  Jose M Marin; Santiago J Carrizo; Eugenio Vicente; Alvar G N Agusti
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Adrenal venous sampling: evaluation of the German Conn's registry.

Authors:  Oliver Vonend; Nora Ockenfels; Xing Gao; Bruno Allolio; Katharina Lang; Knut Mai; Ivo Quack; Andreas Saleh; Christoph Degenhart; Jochen Seufert; Lysann Seiler; Felix Beuschlein; Marcus Quinkler; Petr Podrabsky; Martin Bidlingmaier; Reinhard Lorenz; Martin Reincke; Lars Christian Rump
Journal:  Hypertension       Date:  2011-03-07       Impact factor: 10.190

9.  [Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism].

Authors:  O Vonend; J Stegbauer; P Kokulinsky; S Adams; D Liermann; K Hahn; L C Rump
Journal:  Dtsch Med Wochenschr       Date:  2007-11       Impact factor: 0.628

10.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.